RxDoctor Payments Data

Lindsay Tapia

Nurse Practitioner · Moline, ILNPI 1700239449

Payments from drug & device makers

$895in general payments, 2019–2025

Across 43 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$269
  • Regeneron Healthcare Solutions, Inc.$235
  • GSK$103
  • Vanda Pharmaceuticals Inc.$72
  • Resmed Corp$42
  • AbbVie$33
  • plus $140 from 8 others

What the payments were for

  • Food & beverage$58365%
  • Education$31235%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$895 in reported general payments places this provider in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$22,703
Medicare patients
175
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$81,515
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr115$65,939
Spiriva RespimatTiotropium Bromide67$39,760
Stiolto RespimatTiotropium Br/Olodaterol Hcl78$38,069
Incruse ElliptaUmeclidinium Bromide48$21,335
Bevespi AerosphereGlycopyrrolate/Formoterol Fum33$19,993
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$19,563
DuleraMometasone/Formoterol43$18,151
Breo ElliptaFluticasone/Vilanterol37$16,552
Advair HfaFluticasone Propion/Salmeterol27$12,078
Spiriva HandihalerTiotropium Bromide14$11,439
Arnuity ElliptaFluticasone Furoate41$10,312
SunosiSolriamfetol Hcl11$10,059
SymbicortBudesonide/Formoterol Fumarate33$8,846
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$6,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta$103$195,653345 claims
AstraZenecaBevespi Aerosphere, Breztri Aerosphere, Symbicort$14$48,40295 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Moline

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →